| 1 |
Lv W, Cheng K, Li X, Feng L, Li H, Li J, Chang C, Cao D. Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer. Front Oncol 2021;11:759652. [PMID: 35096571 DOI: 10.3389/fonc.2021.759652] [Reference Citation Analysis]
|
| 2 |
Wang CY, Sheng CC, Ma GL, Xu D, Liu XQ, Wang YY, Zhang L, Cui CL, Xu BH, Song YQ, Zhu J, Jiao Z. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy. Acta Pharmacol Sin 2021;42:1368-75. [PMID: 33154554 DOI: 10.1038/s41401-020-00550-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 3 |
Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
|
| 4 |
Jiang P, Geng L, Mao Z, Wang Q, Wang W, Jiao M, Yao Y, Chen N, Zhang J, Nan K, Shen Y, Guo H, Jiang L. First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Immunotherapy 2022. [PMID: 35259921 DOI: 10.2217/imt-2021-0112] [Reference Citation Analysis]
|
| 5 |
Araujo DV, Uchoa B, Soto-Castillo JJ, Furlan LL, Oliva M. When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Target Oncol 2022;17:253-70. [PMID: 35687223 DOI: 10.1007/s11523-022-00890-1] [Reference Citation Analysis]
|
| 6 |
Cunningham O, Scott M, Zhou ZS, Finlay WJJ. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. MAbs 2021;13:1999195. [PMID: 34780320 DOI: 10.1080/19420862.2021.1999195] [Reference Citation Analysis]
|
| 7 |
Liu L, Liu Y, Gong L, Zhang M, Wu W. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature. Cancer Biol Ther 2020;21:983-9. [PMID: 33092443 DOI: 10.1080/15384047.2020.1829265] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Hwang K, Yoon JH, Lee JH, Lee S. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines 2021;9:39. [PMID: 33466394 DOI: 10.3390/biomedicines9010039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
